Iain Rj MacPherson

Summary

Country: UK

Publications

  1. doi request reprint A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours
    I R Macpherson
    Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
    Eur J Cancer 49:782-9. 2013
  2. pmc Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses
    D Alan Anthoney
    St James Institute of Oncology, University of Leeds and Leeds Teaching Hospitals Trust, Leeds LS9 7TF, United Kingdom
    BMC Cancer 12:536. 2012
  3. pmc Recombinant human epoetin beta in the treatment of chemotherapy-related anemia
    Iain Rj MacPherson
    Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
    Ther Clin Risk Manag 5:261-70. 2009
  4. doi request reprint Current status of cediranib: the rapid development of a novel anti-angiogenic therapy
    Colin R Lindsay
    Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow, G12 0YN, UK
    Future Oncol 5:421-32. 2009

Collaborators

  • Colin R Lindsay
  • Nicholas S Reed
  • D Alan Anthoney
  • T R J Evans
  • Masanori Miwa
  • John M Hartley
  • Christopher Twelves
  • Jay Naik
  • Keith Jones
  • Donna Crawford
  • Tomohisa Saito
  • Masaichi Abe
  • Janet A Hartley

Detail Information

Publications4

  1. doi request reprint A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours
    I R Macpherson
    Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
    Eur J Cancer 49:782-9. 2013
    ..To determine the maximum tolerated dose (MTD) of OSI-930 that can be combined with erlotinib, and establish recommended phase 2 doses when both agents are administered daily in patients with advanced solid tumours...
  2. pmc Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses
    D Alan Anthoney
    St James Institute of Oncology, University of Leeds and Leeds Teaching Hospitals Trust, Leeds LS9 7TF, United Kingdom
    BMC Cancer 12:536. 2012
    ..A Phase I dose escalation first in man study assessed maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and recommended Phase II dose of TP300, a water soluble prodrug of the Topo-1 inhibitor TP3076, and active metabolite, TP3011...
  3. pmc Recombinant human epoetin beta in the treatment of chemotherapy-related anemia
    Iain Rj MacPherson
    Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
    Ther Clin Risk Manag 5:261-70. 2009
    ..In response, regulatory authorities have mandated increasingly restrictive label changes. In light of these new developments we consider the current role of epoetin beta in the management of chemotherapy-related anemia...
  4. doi request reprint Current status of cediranib: the rapid development of a novel anti-angiogenic therapy
    Colin R Lindsay
    Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow, G12 0YN, UK
    Future Oncol 5:421-32. 2009
    ..This article provides a comprehensive and up-to-date synopsis of all pertinent preclinical and clinical studies detailing this promising new therapy...